Giro

Giro is a biotechnology company developing a programmable medicine platform based on epigenome editing. Founded by pioneers in the CRISPR field from UCSF and the Whitehead Institute, the company leverages CRISPRoff and CRISPRon technologies to precisely control gene expression without inducing DNA double-strand breaks. This approach allows for the permanent silencing or activation of genes, offering a potentially safer and more versatile alternative to traditional gene editing. Giro is currently in the pre-clinical stage, focusing on applying its platform to a range of genetic and chronic diseases. The company is backed by top-tier venture capital firms including ARCH Venture Partners and GV.